Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension | Zendy

Russell E. Lewis | Zendy; Dimitrios P. Kontoyiannis | Zendy; Pierluigi Viale | Zendy; Eric Sarpong | Zendy

Open Access

Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension

Author(s) -

Russell E. Lewis,

Dimitrios P. Kontoyiannis,

Pierluigi Viale,

Eric Sarpong

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01435-19

Subject(s) - posaconazole , drug , therapeutic drug monitoring , medicine , intensive care medicine , pharmacology , antifungal , dermatology , voriconazole

Therapeutic drug monitoring (TDM) has been recommended in guidelines for patients receiving posaconazole oral suspension, but its utility in patients receiving posaconazole tablet, which has an improved bioavailability, remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research